289505-11-9Relevant articles and documents
Novel aminoglycosides and uses thereof in the treatment of genetic disorders
-
Page/Page column 19; 26, (2009/04/24)
A new class of paromomycin-derived aminoglycosides, which exhibit efficient stop-codon mutation suppression activity, low toxicity and high selectivity towards eukaryotic cells are provided. Also provided are chemical and chemo-enzymatic processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders.
Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations
Nudelman, Igor,Rebibo-Sabbah, Annie,Shallom-Shezifi, Dalia,Hainrichson, Mariana,Stahl, Ido,Ben-Yosef, Tamar,Baasov, Timor
, p. 6310 - 6315 (2007/10/03)
A series of new derivatives of the clinically used aminoglycoside antibiotic paromomycin were designed, synthesized, and their ability to read-through premature stop codon mutations was examined in both in vitro translation system and ex vivo mammalian cultured cells. One of these structures, a pseudo-trisaccharide derivative, showed notably higher stop codon read-through activity in cultured cells compared to those of paromomycin and gentamicin.